126463-85-2

Basic information

• Product Name: Benzoic acid, 4-(acetylamino)-5-chloro-2-methoxy-3-nitro-, methyl ester
• CAS NO: 126463-85-2
• Molecular Formula: C11H11ClN2O6
• Molecular Weight: 302.671
• Mol File: 126463-85-2.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(acetylamino)-5-chloro-2-methoxy-3-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(acetylamino)-5-chloro-2-methoxy-3-nitro-, methyl ester(126463-85-2)
• EPA Substance Registry System: Benzoic acid, 4-(acetylamino)-5-chloro-2-methoxy-3-nitro-, methyl ester(126463-85-2)

Safety Data

• Hazardous Substances Data: 126463-85-2(Hazardous Substances Data)

Upstream product

• 4093-31-6 methyl 2-methoxy 4-acetamido 5-chloro benzoate 
• 20896-27-9 methyl 4-amino-5-chloro-2-methoxybenzoate 
• 7206-70-4 4-amino-5-chloro-2-methoxybenzoic acid 

Downstream Products

• 1404449-51-9 methyl 4-acetamido-3-amino-2-methoxybenzoate 
• 1312608-71-1 C₄₂H₅₁N₉O₇ 
• 1312610-74-4 C₃₈H₄₅N₇O₅ 
• 1312610-73-3 C₃₆H₄₅N₇O₅ 
• 1312610-72-2 C₃₆H₄₂ClN₇O₇ 
• 1312610-71-1 C₃₇H₄₄ClN₇O₇ 
• 1312610-70-0 C₃₇H₄₄ClN₃O₁₃ 
• 1312610-62-0 C₄₃H₄₈ClN₃O₁₃ 
• 1312610-61-9 C₂₃H₁₆Br₂ClNO₅ 
• 1312611-72-5 C₂₁H₁₂Cl₃NO₅ 
• 1312610-60-8 C₂₁H₁₄ClNO₇ 
• 1312610-59-5 C₂₃H₁₈ClNO₇ 
• 1312610-56-2 C₉H₇BrClNO₅ 
• 457947-63-6 C₁₂H₁₃ClN₂O₆ 

Relevant articles and documents

As neuroprotective agents of pharmaceutical compounds

The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

ORGANIC COMPOUNDS

Compounds of formula (I) in free or salt form, where Y, R1, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the CXCR2 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.